Mermaid Bio develops intrabodies that deliver antibodies directly into diseased cells, targeting intracellular proteins to treat conditions like Hepatocellular Carcinoma. This approach minimizes damage to healthy tissues while addressing the challenge of treating difficult intracellular targets.
Funding
$850K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hepatocellular Carcinoma and other diseases are difficult to treat because current therapies struggle to effectively target intracellular proteins without harming healthy tissues. Delivering antibodies directly into diseased cells to target these intracellular proteins remains a significant challenge.
Solution
Mermaid Bio develops intrabodies, a novel precision-medicine approach that combines the power of antibodies with targeted intracellular drug delivery. Intrabodies deliver antibodies directly into diseased cells, targeting intracellular proteins while minimizing damage to healthy tissues. This approach enables the development of first-in-class therapies against previously intractable targets, offering new hope and improved quality of life for patients. Their lead program focuses on an intrabody that blocks β-catenin in Hepatocellular Carcinoma.
Target Audience
The primary target audience includes patients suffering from diseases like Hepatocellular Carcinoma, as well as healthcare providers and researchers seeking novel, targeted therapies for difficult-to-treat intracellular targets.
Features
- Intrabody-based technology for targeted intracellular drug delivery.
- Antibody-based approach to target specific intracellular proteins.
- Designed to minimize damage to healthy tissues.
- Lead program: Anti-Beta-Catenin Program (ABC) for Hepatocellular Carcinoma.